Glorianna

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glorianna

Quick Facts Table

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Tablet (Oral)
Pharmacological Class Sex Hormones and related agents
Therapeutic Type Combined Oral Contraceptive (COC)
Primary Use Pregnancy Prevention / Contraception
Origin Synthetic (Steroidal Hormone Derivatives)

What Type of Medicine is Glorianna?

Glorianna is a prescription-only medicine that is classified as a Combined Oral Contraceptive (COC) tablet, belonging to the high-level pharmacological class of Sex Hormones and related agents. It is administered via the oral route for systemic administration throughout the body.

The drug is recognized as a highly effective form of birth control, with pharmacological studies confirming its mechanism and efficacy. Glorianna specifically falls within the category of monophasic fixed-dose combination products, where the quantity of its active ingredients remains constant in every active pill, simplifying the hormonal regulation regimen for women of reproductive age.


What Are the Active Ingredients in Glorianna?

The active ingredients are the two synthetic steroid hormones with precise chemical structures: Ethinyl Estradiol and Levonorgestrel. They form an estrogen-progestin combination, delivered in a solid oral formulation vehicle.

Ethinyl Estradiol serves as the synthetic estrogen component, while Levonorgestrel acts as the potent synthetic progestin, which is an analog of progesterone. The combination of these two established, synthetic compounds is a defining feature of the formulation, positioning it alongside many other popular, well-studied contraceptives, such as Aviane and Levora.


What is the Primary Purpose of Glorianna?

The singular, overriding purpose of Glorianna is effective and reliable contraception, specifically pregnancy prevention. This is a globally recognized and pharmacologically confirmed therapeutic purpose for this combination of active ingredients.

The mechanism relies on suppressing the body's hormonal signaling to achieve the core effect of inhibition of ovulation, preventing the release of an egg. Additionally, the hormonal influence alters the female reproductive tract, including thickening the cervical mucus and causing endometrial changes. This multi-level approach maximizes the potential for successful hormonal contraception.

What side effects are possible with Glorianna?

Possible side effects and safety information

The official safety profile for this combined oral contraceptive (Ethinyl Estradiol and Levonorgestrel) is defined by both common, generally expected adverse reactions and the documented risk of rare, serious vascular events.

Adverse Reaction Scope

The most frequent adverse events reported in clinical trials (often classified as Very Common or Common) include headache, nausea, vomiting, weight increased, breast pain, mood changes, and irregular/heavy vaginal bleeding (spotting). These effects typically affect the Gastrointestinal, Nervous System, and Reproductive System organ classes.

Serious Adverse Reactions and Constraints

The medicine is associated with a rare but serious risk of Thromboembolic Disorders, encompassing Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction. The risk of such Arterial and Venous Thrombotic Events is generally highest during the first year of use.

Population-specific constraints define who should not use the medicine. It is strictly contraindicated for females over age 35 who smoke due to a significantly increased risk of serious cardiovascular events. Contraindications also apply to individuals with uncontrolled Hypertension, a history of Migraine with Aura, or severe Hepatic Impairment. The label also notes that unscheduled bleeding and spotting are most common during the first three months of use.

Regulatory Safety Summary

  • The primary regulatory safety focus is the rare, serious risk of vascular and thrombotic events (blood clots), which dictates key contraindications.
  • Routine adverse effects are formally classified by frequency, offering a neutral description of expected reactions affecting various body systems.
  • The safety profile includes explicit population constraints and time-related patterns, such as the period of highest VTE risk being during the first year of use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Glorianna (Ethinyl Estradiol and Levonorgestrel) is defined in official regulatory documents by specific hormonal effects and a low acute toxicity profile. Manifestations typically reported following the ingestion of doses exceeding the prescribed regimen include nausea and vomiting. In females, a common documented sign is withdrawal bleeding (or unscheduled vaginal bleeding), which may commence several days after the over-ingestion event. Other possible symptoms listed in official documents are drowsiness and breast tenderness.

Official regulatory statements consistently classify acute overdosage with this combined oral contraceptive as generally not likely to be life-threatening. Serious ill effects are not commonly reported, even following accidental ingestion of large doses by young children. Due to the lack of a known specific antidote, the mandated management is symptomatic and supportive treatment.

Urgent medical attention is required for any critical, non-hormonal symptoms. Regulatory guidance advises contacting Poison Control or emergency services immediately if the individual experiences signs such as loss of consciousness, difficulty breathing, or sudden, severe pain. These specific manifestations require prompt professional medical assessment.

Therapeutic Uses of Glorianna

What Glorianna Treats: Main Uses and Benefits

Glorianna is primarily recognized for providing effective pregnancy prevention but is also utilized for its systemic therapeutic effects in managing several gynecological and dermatological conditions. Oral contraceptives are sometimes used to treat conditions like heavy or irregular menstruation, endometriosis, and acne. It offers supportive symptomatic relief that helps patients cope more steadily with difficult episodes across various domains.


The medication is commonly used across conditions presenting with episodic or recurrent manifestations, assisting with cycle regulation, reducing severe menstrual pain (dysmenorrhea) and excessive menstrual blood loss (menorrhagia), and assisting with the management of hormonally-driven acne and hirsutism. Its use is relevant in the management of conditions including Polycystic Ovary Syndrome (PCOS) and endometriosis.

“This use is relevant for easing challenging manifestations that create noticeable functional strain.”

Quick Fact: Support for Menstrual Symptoms Glorianna is commonly used to help with symptom clusters that may become intense or disruptive, such as those related to heavy bleeding or severe monthly pain, contributing to improved day-to-day comfort.


This use provides symptomatic assistance that is relevant in conditions characterized by periods of heightened symptoms, helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility to Use Glorianna: Official Regulatory Summary

Glorianna (lorlatinib) is indicated for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. A U.S. Food and Drug Administration (FDA)-approved test is required to confirm the ALK-positive status before starting treatment.

Populations That Must Not Use This Medicine

  • Strong CYP3A Inducers: The medicine is formally contraindicated for patients who are taking strong CYP3A inducers (such as rifampin or St. John’s Wort). Using these agents together can lead to serious hepatotoxicity (liver injury).
  • ILD/Pneumonitis: Patients who develop treatment-related Interstitial Lung Disease (ILD) or pneumonitis of any severity must permanently discontinue the medicine.

Special Considerations and Restrictions

Population/Condition Eligibility Status or Restriction
Pediatric Use Safety and effectiveness are not established in children.
Pregnancy Can cause fetal harm based on animal studies. Effective non-hormonal contraception must be used by women of reproductive potential during treatment and for six months after the final dose.
Lactation Advise not to breastfeed during treatment and for a period after the final dose due to potential serious adverse reactions in the infant.
Severe Renal Impairment Requires a dosage modification.

Discontinuation or dose reduction may also be required for patients experiencing severe heart problems (recurrent complete AV block without a pacemaker), high blood pressure, or uncontrolled high blood sugar while on therapy.

What should I know about interactions with other medicines?

Glorianna Interactions with other medicines and products

Drug interactions occur when a medicine’s effects are altered by the simultaneous use of another substance, which can include other prescription drugs, over-the-counter products, or certain supplements. For Glorianna, the most important known interactions are primarily related to its metabolism by specific liver enzymes.

Authoritative pharmacological sources indicate that Glorianna is a substrate for the cytochrome P450 3A4 (CYP3A4) enzyme system. This is a critical pathway responsible for the elimination of numerous medications. Consequently, co-administering Glorianna with products that strongly inhibit CYP3A4 activity can significantly increase the concentration of Glorianna in the body, raising the risk of adverse effects. Conversely, using Glorianna with strong CYP3A4 inducers (substances that speed up the enzyme's activity) may lead to reduced drug concentrations, potentially decreasing the therapeutic effectiveness of Glorianna.

Interaction Type Interacting Product Category Potential Effect on Glorianna
Avoid/Contraindicated Strong CYP3A4 Inducers (e.g., certain antibiotics, seizure medicines) Significantly reduces Glorianna effectiveness
Use with Caution Strong CYP3A4 Inhibitors (e.g., certain antifungal or HIV medicines) Significantly increases Glorianna concentration and potential side effects
Other CYP3A4 Substrates Potential for mutual interaction; clinical monitoring may be required

Patients should inform their healthcare provider of all medicines and supplements currently being taken to properly assess and manage any potential drug interactions.

Mechanism of Action

Central Suppression of the HPG Axis

Glorianna's primary mechanism involves the two synthetic hormones acting as agonists at the Estrogen and Progesterone Receptors in the hypothalamus and pituitary gland. This receptor activation triggers a negative feedback loop that inhibits the release of GnRH and, crucially, blocks the mid-cycle surge of Luteinizing Hormone (LH). This leads directly to Anovulation—the physiological prevention of egg release—which constitutes the primary mechanistic step.


Peripheral Barrier and Mucus Alteration

The second mechanistic domain is a peripheral action where the progestin component, Levonorgestrel, acts on receptors in the cervix to increase the viscosity and density of the cervical mucus. This creates a physical barrier that is highly restrictive and hostile to sperm movement. Concurrently, the combined hormones cause atrophy and structural changes in the endometrium (uterine lining), rendering the tissue unreceptive. These two peripheral mechanisms constitute mechanistic redundancy, supporting the central action with layers of biological constraint. These three distinct, overlapping physiological changes establish a multi-level mechanistic barrier.

Dosage and Administration Information

Glorianna is strictly intended for oral administration as a fixed-dose combination tablet. The general principle for its use is based on a standardized, cyclical regimen that requires precise adherence to ensure hormonal consistency. The medicine is prescribed as one tablet daily and must be taken at the same time every day to maintain the established schedule.

The active tablet typically contains a fixed combination of ingredients, such as Levonorgestrel 0.15 mg and Ethinyl Estradiol 0.03 mg. This regimen is predominantly structured as a 28-day course, where 21 consecutive days involve taking the active hormonal tablets, followed by seven days of taking inactive (placebo) tablets or having a hormone-free interval. This entire cycle must be followed in the sequence directed on the blister packaging, and a new pack is started immediately after the previous one finishes, with no gap between packs.

Official usage instructions specify that the daily tablet may be taken without regard to meals. Key procedural constraints also dictate the management of the regimen: specific protocols, which differ based on the number of tablets missed and the week of the cycle, exist for handling a missed active tablet. Furthermore, the official use is strictly confined to post-menarchal women and is not indicated in postmenopausal women.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Glorianna


Evidence for Use in Pregnancy Prevention

Research exploring this medicine was primarily conducted in the context of pregnancy prevention, involving Pivotal Phase 3 Randomized Controlled Trials (RCTs) and multicenter trials. These studies were applied in research exploring healthy women of reproductive age. Researchers examined the Pregnancy Incidence Rate, quantified by the Pearl Index (PI). Research examined adherence patterns, monitoring the differences in PI between perfect use and typical use. Long-term population-level data is tracked by large, observational settings evaluating daily-life functioning.

️ Evidence for Managing Menstrual Symptoms

Research explored the active ingredients of Glorianna in populations with symptoms related to conditions characterized by fluctuating or episodic manifestations, specifically severe menstrual pain (dysmenorrhea) and irregular menstrual cycles. The research base includes Systematic Reviews and RCTs that compared the active ingredients to an inactive substance (placebo). Studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning. Comparative evidence is lacking for direct head-to-head comparisons between this specific formulation and every other hormonal treatment for pain and cycle management.

Research on Hormonally-Driven Skin Conditions

Glorianna was evaluated in women presenting with certain skin conditions, including Acne Vulgaris and Hirsutism (excess body hair). Research designs included Comparative Clinical Studies, often testing this formulation against other active hormonal contraceptive products. Studies monitored outcomes related to systemic or functional imbalance using specific tools, such as clinical grading systems for acne severity. Findings were mixed across studies that examined influence, and evidence is limited regarding the direct, standalone influence of this specific formulation on skin conditions.

Key Studies & References

  1. Efficacy and Safety of a Levonorgestrel/Ethinyl Estradiol Regimen in Healthy Women (Pivotal Trial Structure)
  2. Return of Ovulation and Fecundity After Cessation of an Extended Regimen of Levonorgestrel/Ethinyl Estradiol

Frequently Asked Questions (FAQ)

Common questions about Glorianna (FAQ)

Q: What is the main reason Glorianna is prescribed?

Regulatory documents state that the primary indication for this medication is the prevention of pregnancy in females who have begun menstruating. Studies also explore its use for managing certain menstrual symptoms and hormonally-driven skin conditions.

Q: Is Glorianna considered a new type of medication?

The active ingredients in Glorianna are well-established hormonal components. The combination of levonorgestrel and ethinyl estradiol has been available for use in oral contraceptives since the 1970s.

Q: Can Glorianna be taken long-term?

Studies and official guidance suggest that combined oral contraceptives may be suitable for extended use over multiple years, especially for healthy, non-smoking individuals. Continuous use is typically done under the observation of a healthcare provider.

Q: Do I need to change my diet while using Glorianna?

Official documents state that the tablet can be taken without regard to meals. Regulatory information suggests that monitoring of blood sugar levels may be necessary for individuals with pre-existing diabetes or prediabetes due to potential metabolic effects.

Q: Is Glorianna a controlled substance?

According to regulatory schedules, Glorianna is typically not classified as a controlled substance in the United States.

Q: Can Glorianna affect my sleep?

Official safety documents indicate that insomnia (difficulty sleeping) has been reported as a potential side effect, usually identified through postmarketing surveillance after the drug was released.

Q: Is it normal to feel a little tired when first taking Glorianna?

Clinical profiles indicate that fatigue or unusual tiredness has been noted as an uncommon side effect among users. The official safety summary classifies this as a less frequent event.

Q: Is it safe to drink coffee or caffeine while taking Glorianna?

Official interaction data suggests that the estrogen component in Glorianna may increase the concentration of caffeine in the bloodstream.

Q: What if I have kidney problems—can I still use Glorianna?

Regulatory documents indicate that caution is necessary for individuals with renal (kidney) dysfunction. This is because the medicine’s hormonal components may cause fluid retention, which can exacerbate existing kidney conditions.

Q: Can Glorianna be used during pregnancy?

The medicine is not intended for use once pregnancy is established. Regulatory guidelines advise that the drug should be discontinued immediately upon confirmed pregnancy, as there is no therapeutic purpose for a contraceptive during that time.

Q: Does Glorianna have a boxed warning, and what does it mean?

The official product label contains a Boxed Warning. This is a regulatory requirement that highlights a significantly increased risk of serious cardiovascular events, particularly for women over the age of 35 who smoke.

Q: Are there specific tests I need before starting Glorianna?

Official patient counseling advises that a healthcare provider may perform a physical examination and order certain laboratory tests before or during the start of treatment.

Q: Does Glorianna make you more sensitive to the sun?

Reports of phototoxic skin reactions, which involve increased sensitivity to sunlight, have been associated with the active ingredients in this medication.

Q: Has Glorianna been approved in other countries besides the U.S.?

The active components in Glorianna are approved and used in combined oral contraceptives in numerous regions worldwide, including those governed by the regulatory bodies of Europe and Canada.

Q: How does the drug stay in the body after I stop taking Glorianna?

The active hormones are processed (metabolized) by the liver. Official documents contain detailed pharmacokinetics data which describes the rate at which the body breaks down and eliminates the drug components.

Q: Is the active ingredient in Glorianna available in a generic version?

Generic versions of combined oral contraceptive medications containing the same active ingredients have been approved by the FDA.

Q: Does Glorianna affect blood sugar levels?

The product may reduce glucose tolerance (the body's ability to process sugar). Therefore, regulatory warnings note that monitoring of blood glucose levels may be necessary for individuals with pre-existing diabetes or prediabetes.

Q: What information is provided in the official patient leaflet for Glorianna?

Official patient leaflets (like the Medication Guide) contain mandatory safety information. This includes details on serious warnings (such as vascular risks), contraindications (who should not use it), and guidance on common side effects and administration.

Q: Is Glorianna addictive?

Official safety documents and regulatory reviews describe combined oral contraceptives as having a very low potential for drug abuse or addiction.

Q: Are there any known issues with taking Glorianna before or after surgery?

Official warnings state that to minimize vascular risks, the medication may be required to be stopped at least four weeks before and for two weeks following any major surgery.

Q: How is Glorianna usually packaged?

The product is supplied in a 28-tablet cycle format. The tablets are often divided into active hormonal phases and inactive (placebo) phases, which are typically distinguished by different tablet colors.

Q: Is Glorianna related to any older, discontinued medicines?

Regulatory context notes that the active component ethinyl estradiol is related to older hormonal medicines. It is described as having replaced mestranol in many contraceptive pills after its introduction decades ago.

Q: How soon after starting Glorianna might I notice anything?

The primary therapeutic effect, which is the prevention of ovulation, is described in official documents as beginning after a specific number of consecutive active tablets are taken. Changes in expected side effects, like spotting, are often noted during the first three months of use.

Q: Are there common skin reactions associated with Glorianna?

Clinical data reports common adverse reactions including rash. Official research has also examined the medicine's influence in women presenting with certain hormonally-driven skin conditions, such as acne.

Q: Does Glorianna interact with vitamins or supplements?

Official labeling advises that the drug may interact with certain supplements, including herbal products, that affect liver enzymes. These interactions can potentially alter the amount of medication in the body.

Q: Are there any specific foods or drinks to avoid while using Glorianna?

Official guidance advises monitoring metabolic effects (like blood glucose and lipids) in certain populations. Furthermore, interaction data suggests that the estrogen component may increase the level of caffeine in the blood.

Q: Is there research looking at Glorianna use in children?

Regulatory documents state that the medicine is strictly confined to use by post-menarchal females. This refers to females who have begun menstruating, typically adolescents, and is not indicated for younger children.

Q: What does the research say about how well Glorianna works?

Research exploring the use of combined oral contraceptives in pregnancy prevention commonly uses the Pearl Index (PI) to quantify the pregnancy incidence rate observed in studies. Studies monitor outcomes for both 'perfect use' (strict adherence) and 'typical use' (real-world adherence).

Q: Is Glorianna considered safe to use with heart medication?

Due to the rare but serious risks of arterial and venous thrombotic events (blood clots), the medicine is generally contraindicated in individuals with established cardiovascular disease, such as uncontrolled hypertension. The assessment of specific interactions with heart medications is typically performed by a healthcare provider.

Q: What is the typical duration of treatment with Glorianna?

The medicine is administered via a continuous 28-day cycle. Regulatory studies have explored the safety profile of extended use of this medication over multiple years in healthy women of reproductive age.

Q: Are there any long-term effects of Glorianna that studies have reported?

Long-term monitoring studies track various health outcomes. These include the rare but serious risk of vascular blood clots, as well as the potential for structural changes in the uterine lining tissue.

Q: What are the common reasons people stop taking Glorianna?

The most common reasons for treatment discontinuation observed in clinical studies are related to frequent adverse events. These include irregular bleeding or spotting, headache, and nausea.

How should Glorianna be stored and disposed of?

How to Store and Dispose of Glorianna

The storage and disposal of Glorianna (Ethinyl Estradiol/Levonorgestrel) tablets must follow strict regulatory guidelines to maintain the stability of the hormonal components and ensure environmental safety.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C.
Protection Keep protected from moisture, excessive heat, and do not freeze.
Container Keep the medicine in its original container and store with the container tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Glorianna tablets must be disposed of according to local requirements. The medication must not be discarded via wastewater (flushing) or placed in household waste. It should be returned to a pharmacy or designated collection site for proper regulatory disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glorianna found in:

A-Z Index: